TSHA (Taysha Gene Therapies) Tariff Resilience Score: 8/10 (As of Sep. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSHA Taysha Gene Therapies Inc TSHA
33 GF Score
Price $5.02
GF Value $0.52
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Taysha Gene Therapies Tariff Resilience Score?

Taysha Gene Therapies TSHA -2.71% 33 Tariff Resilience Score is 8 as of Sep. 13, 2026. GuruFocus rates TSHA with a GF Score™ of 33/100 and a GF Value™ of $0.52 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,356 Biotechnology companies, Taysha Gene Therapies ranks better than 98.67% on this metric.

Taysha Gene Therapies has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Taysha Gene Therapies has Taysha Gene Therapies primarily operates in the US with minimal international trade exposure. Its focus on R&D and domestic market reduces tariff risks. The biotech industry often benefits from exemptions, enhancing resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Taysha Gene Therapies might have Highly Resilient.

Taysha Gene Therapies  (NAS:TSHA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Taysha Gene Therapies Tariff Resilience Score Related Terms

TSHA vs KARD, GHRS, VIR: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Taysha Gene Therapies's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taysha Gene Therapies Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Taysha Gene Therapies's Tariff Resilience Score falls into.


TSHA
33GF Score
Taysha Gene Therapies Inc TSHA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Taysha Gene Therapies (TSHA) has a Tariff Resilience Score of 8 as of Sep. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Taysha Gene Therapies ranks #18 out of 1356 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Taysha Gene Therapies' Tariff Resilience Score too high?
Taysha Gene Therapies' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Taysha Gene Therapies' value of 8 is 100% above this industry median. Based on the distribution chart, Taysha Gene Therapies ranks #18 out of 1356 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' Tariff Resilience Score compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #18 out of 1356 companies for Tariff Resilience Score. This places Taysha Gene Therapies in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Taysha Gene Therapies' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,356 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taysha Gene Therapies's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taysha Gene Therapies's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $5.02 — trading 865.4% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current Tariff Resilience Score is 8 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taysha Gene Therapies (TSHA) Overvalued in 2026?

Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued. The current stock price of $5.02 is trading 865.4% above its estimated GF Value™ of $0.52. GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.

Key valuation signals for TSHA:

  • Tariff Resilience Score: 8
  • GF Value™: $0.52 vs. price of $5.02 (865.4% above fair value)
  • GF Score™: 33/100 with 2 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1356)

No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taysha Gene Therapies Business Description

Address 3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score

Get the complete analysis for TSHA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.02
Price
$0.52
GF Value